1277 related articles for article (PubMed ID: 11686352)
1. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
2. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding.
Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF
Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351
[TBL] [Abstract][Full Text] [Related]
3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion of recombinant factor VIIa: continue or not?
Ewenstein BM
Thromb Haemost; 2001 Oct; 86(4):942-4. PubMed ID: 11686349
[No Abstract] [Full Text] [Related]
5. Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII.
Schulman S; Tjønnfjord GE; Wallensten R; Martinowitz U; Kenet G
Thromb Haemost; 2005 Dec; 94(6):1177-80. PubMed ID: 16411390
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients.
Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865
[TBL] [Abstract][Full Text] [Related]
9. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
[TBL] [Abstract][Full Text] [Related]
10. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J
Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194
[TBL] [Abstract][Full Text] [Related]
11. [Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors].
Nakamura M; Terashima K; Takashima Y; Amano K; Horikoshi Y; Mimaya J
Rinsho Ketsueki; 2002 Mar; 43(3):183-8. PubMed ID: 11979750
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation.
Ludlam CA; Smith MP; Morfini M; Gringeri A; Santagostino E; Savidge GF
Br J Haematol; 2003 Mar; 120(5):808-13. PubMed ID: 12614214
[TBL] [Abstract][Full Text] [Related]
14. Experiences with continuous infusion of recombinant activated factor VII.
Schulman S; d'Oiron R; Martinowitz U; Pasi J; Briquel ME; Mauser-Bunschoten E; Morfini M; Ritchie B; Goudemand J; Lloyd J; McPherson J; Négrier C; Peerlinck K; Petrini P; Tusell J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S97-101. PubMed ID: 9819037
[TBL] [Abstract][Full Text] [Related]
15. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
Łaguna P; Mital A
Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
[TBL] [Abstract][Full Text] [Related]
16. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative use of recombinant activated factor VII (rFVIIa).
De Gasperi A
Minerva Anestesiol; 2006 Jun; 72(6):489-94. PubMed ID: 16682921
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with activated factor VII: focus on safety aspects.
Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
[TBL] [Abstract][Full Text] [Related]
19. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
20. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
